Recent progress in application of nanovaccines for enhancing mucosal immune responses.
10.1016/j.apsb.2022.08.010
- Author:
Guangsheng DU
1
;
Ming QIN
1
;
Xun SUN
1
Author Information
1. Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
- Publication Type:Review
- Keywords:
Adjuvants;
Cell targeting;
Infectious diseases;
M cells;
Mucosal immune system;
Mucosal vaccines;
Mucus adhesion and penetration;
Nanovaccines
- From:
Acta Pharmaceutica Sinica B
2023;13(6):2334-2345
- CountryChina
- Language:English
-
Abstract:
Mucosal vaccines that stimulate both mucosal and systemic immune responses are desirable, as they could prevent the invading pathogens at their initial infection sites in a convenient and user-friendly way. Nanovaccines are receiving increasing attention for mucosal vaccination due to their merits in overcoming mucosal immune barriers and in enhancing immunogenicity of the encapsulated antigens. Herein, we summarized several nanovaccine strategies that have been reported for enhancing mucosal immune responses, including designing nanovaccines that have superior mucoadhesion and mucus penetration capacity, designing nanovaccines with better targeting efficiency to M cells or antigen-presenting cells, and co-delivering adjuvants by using nanovaccines. The reported applications of mucosal nanovaccines were also briefly discussed, including prevention of infectious diseases, and treatment of tumors and autoimmune diseases. Future research progresses in mucosal nanovaccines may promote the clinical translation and application of mucosal vaccines.
